Volrustomig
drugOn this page
Also known as Medi 5752MEDI-5752MEDI5752
Summary
Volrustomig (CHEMBL5095362) is a phase-3 clinical-stage antibody; indicated across 9 conditions including head and neck squamous cell carcinoma and mesothelioma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 9 conditions
- Clinical trials: 25
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095362 |
| Name | Volrustomig |
| Type | Antibody |
| Max phase | 3 |
Also known as: Medi 5752, MEDI-5752, MEDI5752, Volrustomig, VOLRUSTOMIG
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| head and neck squamous cell carcinoma | 3 | MONDO:0010150 | EFO:0000181 |
| mesothelioma | 3 | MONDO:0005065 | EFO:0000588 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| gastric neoplasm | 2 | MONDO:0021085 | MONDO:0001056 |
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 25.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE1 | 7 |
| PHASE3 | 5 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05984277 | PHASE3 | ACTIVE_NOT_RECRUITING | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. |
| NCT06079671 | PHASE3 | RECRUITING | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) |
| NCT06097728 | PHASE3 | RECRUITING | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma |
| NCT06129864 | PHASE3 | RECRUITING | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy |
| NCT07000149 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC |
| NCT04379596 | PHASE2 | RECRUITING | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) |
| NCT05061550 | PHASE2 | RECRUITING | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer |
| NCT05489211 | PHASE2 | RECRUITING | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) |
| NCT05702229 | PHASE2 | RECRUITING | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT05775159 | PHASE2 | RECRUITING | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer |
| NCT05888857 | PHASE2 | NOT_YET_RECRUITING | MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. |
| NCT06448754 | PHASE2 | RECRUITING | Volrustomig Priming Regimens Exploratory Phase II Platform Study |
| NCT06535607 | PHASE2 | RECRUITING | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors |
| NCT06792695 | PHASE2 | RECRUITING | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer |
| NCT06943833 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) |
| NCT07065630 | PHASE2 | RECRUITING | Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer |
| NCT03530397 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors |
| NCT03819465 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC |
| NCT04522323 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma |
| NCT04612751 | PHASE1 | ACTIVE_NOT_RECRUITING | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT04686305 | PHASE1 | RECRUITING | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC |
| NCT05821231 | PHASE1 | ACTIVE_NOT_RECRUITING | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma |
| NCT05685472 | PHASE1 | COMPLETED | MEDI5752 in Japanese Patients With Advanced Solid Tumors. |
| NCT04541108 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies |
| NCT06366451 | EARLY_PHASE1 | RECRUITING | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).